HK Stock MarketDetailed Quotes

02126 JW THERAP-B

Watchlist

1.290
-0.010-0.77%

Market Closed Dec 27 16:08 CST

535.93MMarket Cap-0.78P/E (TTM)

JW THERAP-B Key Stats

Cash Flow

All

YOY

Hide blank lines

(Q6)Jun 30, 2024

(FY)Dec 31, 2023

(Q6)Jun 30, 2023

(FY)Dec 31, 2022

(Q6)Jun 30, 2022

(FY)Dec 31, 2021

(Q6)Jun 30, 2021

(FY)Dec 31, 2020

(Q6)Jun 30, 2020

(FY)Dec 31, 2019

Turnover

-1.05%86.82M

19.32%173.86M

32.93%87.74M

373.10%145.7M

--66.01M

--30.8M

----

Operating income

-1.05%86.82M

19.32%173.86M

32.93%87.74M

373.10%145.7M

66.01M

30.8M

Cost of sales

-0.33%-43.07M

1.51%-85.64M

-0.12%-42.93M

-299.71%-86.95M

---42.88M

---21.75M

----

Operating expenses

-0.33%-43.07M

1.51%-85.64M

-0.12%-42.93M

-299.71%-86.95M

-42.88M

-21.75M

Gross profit

-2.38%43.75M

50.14%88.22M

93.74%44.81M

549.60%58.76M

23.13M

9.05M

Selling expenses

-26.60%-76.17M

40.70%-113.2M

28.75%-60.17M

-11.80%-190.88M

-82.88%-84.45M

-1,186.80%-170.73M

---46.18M

---13.27M

----

Administrative expenses

24.73%-59.23M

22.09%-140.05M

13.45%-78.69M

10.80%-179.76M

13.49%-90.92M

12.87%-201.52M

-29.74%-105.1M

-217.31%-231.29M

-216.98%-81.01M

-76.67%-72.89M

Research and development expenses

30.26%-151.01M

-1.42%-413.62M

-10.54%-216.53M

1.59%-407.82M

-5.59%-195.89M

-84.00%-414.4M

-125.50%-185.51M

-65.47%-225.22M

-51.63%-82.27M

-79.11%-136.11M

Special items of operating profit

93.89%-4.85M

-54.92%-210.97M

5.36%-79.34M

-835.36%-136.18M

-2,713.15%-83.83M

-36.01%18.52M

-35.35%3.21M

570.19%28.94M

1,793.52%4.96M

-13.92%4.32M

Operating profit

36.52%-247.51M

7.74%-789.61M

9.73%-389.92M

-12.75%-855.88M

-29.49%-431.96M

-72.19%-759.08M

-110.71%-333.58M

-115.38%-440.84M

-97.63%-158.31M

-82.37%-204.68M

Financing income

-11.86%13.3M

105.78%34.03M

179.41%15.09M

99.31%16.54M

179.21%5.4M

141.09%8.3M

1,434.92%1.93M

89.07%3.44M

-18.71%126K

66.67%1.82M

Financing cost

-8.42%-6.05M

-82.92%-12.42M

-106.85%-5.58M

-152.12%-6.79M

-402.61%-2.7M

-249.61%-2.69M

-85.17%-537K

43.01%-770K

67.19%-290K

53.69%-1.35M

Special items of earning before tax

----

104.17%51.15M

110.47%51.49M

-185.67%-1.23B

-77.43%-491.55M

-170.59%-429.05M

Earning before tax

36.84%-240.27M

9.23%-768M

11.38%-380.42M

-20.48%-846.14M

-52.93%-429.25M

57.79%-702.33M

56.82%-280.7M

-162.74%-1.66B

-81.64%-650.03M

-132.29%-633.26M

After-tax profit from continuing operations

36.84%-240.27M

9.23%-768M

11.38%-380.42M

-20.48%-846.14M

-52.93%-429.25M

57.79%-702.33M

56.82%-280.7M

-162.74%-1.66B

-81.64%-650.03M

-132.29%-633.26M

Earning after tax

36.84%-240.27M

9.23%-768M

11.38%-380.42M

-20.48%-846.14M

-52.93%-429.25M

57.79%-702.33M

56.82%-280.7M

-162.74%-1.66B

-81.64%-650.03M

-132.29%-633.26M

Profit attributable to shareholders

36.84%-240.27M

9.23%-768M

11.38%-380.42M

-20.48%-846.14M

-52.93%-429.25M

57.79%-702.33M

56.82%-280.7M

-162.74%-1.66B

-81.64%-650.03M

-132.29%-633.26M

Basic earnings per share

37.63%-0.58

9.22%-1.87

11.43%-0.93

-17.05%-2.06

-47.89%-1.05

86.04%-1.76

92.87%-0.71

-29.47%-12.61

-80.76%-9.96

-132.46%-9.74

Diluted earnings per share

37.63%-0.58

9.22%-1.87

11.43%-0.93

-17.05%-2.06

-47.89%-1.05

86.04%-1.76

92.87%-0.71

-29.47%-12.61

-80.76%-9.96

-132.46%-9.74

Currency Unit

CNY

Accounting Standards

IAS

Audit Opinions

Unqualified Opinion

Auditor

PricewaterhouseCoopers

	(Q6)Jun 30, 2024	(FY)Dec 31, 2023	(Q6)Jun 30, 2023	(FY)Dec 31, 2022	(Q6)Jun 30, 2022	(FY)Dec 31, 2021	(Q6)Jun 30, 2021	(FY)Dec 31, 2020	(Q6)Jun 30, 2020	(FY)Dec 31, 2019
Turnover	-1.05%86.82M	19.32%173.86M	32.93%87.74M	373.10%145.7M	--66.01M	--30.8M	----	----	----	----
Operating income	-1.05%86.82M	19.32%173.86M	32.93%87.74M	373.10%145.7M	66.01M	30.8M
Cost of sales	-0.33%-43.07M	1.51%-85.64M	-0.12%-42.93M	-299.71%-86.95M	---42.88M	---21.75M	----	----	----	----
Operating expenses	-0.33%-43.07M	1.51%-85.64M	-0.12%-42.93M	-299.71%-86.95M	-42.88M	-21.75M
Gross profit	-2.38%43.75M	50.14%88.22M	93.74%44.81M	549.60%58.76M	23.13M	9.05M
Selling expenses	-26.60%-76.17M	40.70%-113.2M	28.75%-60.17M	-11.80%-190.88M	-82.88%-84.45M	-1,186.80%-170.73M	---46.18M	---13.27M	----	----
Administrative expenses	24.73%-59.23M	22.09%-140.05M	13.45%-78.69M	10.80%-179.76M	13.49%-90.92M	12.87%-201.52M	-29.74%-105.1M	-217.31%-231.29M	-216.98%-81.01M	-76.67%-72.89M
Research and development expenses	30.26%-151.01M	-1.42%-413.62M	-10.54%-216.53M	1.59%-407.82M	-5.59%-195.89M	-84.00%-414.4M	-125.50%-185.51M	-65.47%-225.22M	-51.63%-82.27M	-79.11%-136.11M
Special items of operating profit	93.89%-4.85M	-54.92%-210.97M	5.36%-79.34M	-835.36%-136.18M	-2,713.15%-83.83M	-36.01%18.52M	-35.35%3.21M	570.19%28.94M	1,793.52%4.96M	-13.92%4.32M
Operating profit	36.52%-247.51M	7.74%-789.61M	9.73%-389.92M	-12.75%-855.88M	-29.49%-431.96M	-72.19%-759.08M	-110.71%-333.58M	-115.38%-440.84M	-97.63%-158.31M	-82.37%-204.68M
Financing income	-11.86%13.3M	105.78%34.03M	179.41%15.09M	99.31%16.54M	179.21%5.4M	141.09%8.3M	1,434.92%1.93M	89.07%3.44M	-18.71%126K	66.67%1.82M
Financing cost	-8.42%-6.05M	-82.92%-12.42M	-106.85%-5.58M	-152.12%-6.79M	-402.61%-2.7M	-249.61%-2.69M	-85.17%-537K	43.01%-770K	67.19%-290K	53.69%-1.35M
Special items of earning before tax	----	----	----	----	----	104.17%51.15M	110.47%51.49M	-185.67%-1.23B	-77.43%-491.55M	-170.59%-429.05M
Earning before tax	36.84%-240.27M	9.23%-768M	11.38%-380.42M	-20.48%-846.14M	-52.93%-429.25M	57.79%-702.33M	56.82%-280.7M	-162.74%-1.66B	-81.64%-650.03M	-132.29%-633.26M
After-tax profit from continuing operations	36.84%-240.27M	9.23%-768M	11.38%-380.42M	-20.48%-846.14M	-52.93%-429.25M	57.79%-702.33M	56.82%-280.7M	-162.74%-1.66B	-81.64%-650.03M	-132.29%-633.26M
Earning after tax	36.84%-240.27M	9.23%-768M	11.38%-380.42M	-20.48%-846.14M	-52.93%-429.25M	57.79%-702.33M	56.82%-280.7M	-162.74%-1.66B	-81.64%-650.03M	-132.29%-633.26M
Profit attributable to shareholders	36.84%-240.27M	9.23%-768M	11.38%-380.42M	-20.48%-846.14M	-52.93%-429.25M	57.79%-702.33M	56.82%-280.7M	-162.74%-1.66B	-81.64%-650.03M	-132.29%-633.26M
Basic earnings per share	37.63%-0.58	9.22%-1.87	11.43%-0.93	-17.05%-2.06	-47.89%-1.05	86.04%-1.76	92.87%-0.71	-29.47%-12.61	-80.76%-9.96	-132.46%-9.74
Diluted earnings per share	37.63%-0.58	9.22%-1.87	11.43%-0.93	-17.05%-2.06	-47.89%-1.05	86.04%-1.76	92.87%-0.71	-29.47%-12.61	-80.76%-9.96	-132.46%-9.74
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS
Audit Opinions	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion
Auditor	--	PricewaterhouseCoopers	--	PricewaterhouseCoopers	--	PricewaterhouseCoopers	--	PricewaterhouseCoopers	--	PricewaterhouseCoopers

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Heat List

Overall

No Data

Investment Theme

Pharmaceutical Companies

Intraday-0.61%

02126 JW THERAP-B

JW THERAP-B Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow